Cargando…
Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529882/ https://www.ncbi.nlm.nih.gov/pubmed/34721849 http://dx.doi.org/10.1002/ccr3.4935 |